Pharmaceutical - Anti-virals


Current filters:


Popular Filters

76 to 100 of 307 results

AHF sues Johnson & Johnson over AIDS drug pricing

AHF sues Johnson & Johnson over AIDS drug pricing


The Washington DC, USA-based AIDS Healthcare Foundation (AHF) has filed a law suit in the Superior Court…

Anti-viralsJanssenJohnson & JohnsonLegalNorth AmericaPharmaceuticalPricing

First ever flu vaccine developed by Chinese researchers


Chinese researchers have successfully developed the vaccine for the H7N9 bird flu virus, after the flu…

Anti-viralsAsia-PacificPharmaceuticalResearchTianyuan Bio-Pharmaceutical

EMA advises on compassionate use of sofosbuvir for hepatitis C

EMA advises on compassionate use of sofosbuvir for hepatitis C


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given an…

Anti-viralsEuropeGilead SciencesPharmaceuticalRegulationsofosbuvir

DC AIDS protesters join push to demand China gives $1 billion to fight global AIDS


The Washington DC, USA based AIDS Healthcare Foundation (AHF) is spearheading a series of US and global…


Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C


Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

FDA grants Merck’s hepatitis C treatment breakthrough designation

FDA grants Merck’s hepatitis C treatment breakthrough designation


US pharma giant Merck & Co has announced that the US Food and Drug Administration has granted MK-5172/MK-8742…

Anti-viralsMerck & CoNorth AmericaPharmaceuticalRegulation

Deal worth $156m to provide HIV drugs for Africa


The Global Fund to Fight AIDS, tuberculosis and malaria has signed a $156 million grant agreement with…

Anti-viralsHealthcarePharmaceuticalRest of the World

Janssen-Cilag files European approval of combination medicine for HIV-1


US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C


The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

ViiV Healthcare presents positive Tivicay results from HIV study


Positive data has been reported from the Phase IIIb/IV FLAMINGO study of Tivicay (dolutegravir) versus…

Anti-viralsNorth AmericaPharmaceuticalResearchTivicayViiV Healthcare

AHF sues GSK for failing to provide discounts on HIV/AIDS drugs


The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

Roche in up to $422.5 million deal with Inovio Pharma


Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Boehringer Ingelheim links with Presidio on interferon-free hepatitis C treatment regimens


The US subsidiary of German family-owned drug major Boehringer Ingelheim says it has completed patient…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalPPI-668Presidio PharmaceuticalsResearch

Medivir and Daewoong drop hep C drug candidate


Swedish infectious disease drug developer Medivir (STO:MVIR-B) said on Friday (September 6) that it has…


In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"


As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

FDA approves new ViiV Healthcare HIV drug


The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

AHF claims victory over FDA in HIV prevention drug case


The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

US FDA approves shipment of quadrivalent flu vaccine to health care providers


The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says it has received Food and Drug Administration…

Anti-viralsFluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Roche strikes deal with Medicines Patent Pool on medicines access


Swiss drug major Roche (ROG: SIX) has entered into an agreement with the Medicines Patent Pool, a Geneva,…

Anti-viralsMarkets & MarketingPharmaceuticalPricingRocheValcyte

Vertex slumps as FDA delays hepatitis C trial


US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

New Zealand consults on Victrelis listing and some Pegasys amendments


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children


In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Annual approvals of new drugs for neglected diseases nearly doubled since early 2000s and 2009-12; Tufts


The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent…

Anti-viralsPharmaceuticalRegulationResearchTropical diseases

76 to 100 of 307 results

Back to top